Summary
This phase I study was conducted to reevaluate the dose-limiting toxicities, maximum tolerated (MTD) and recommended phase II doses of oral NMF administered on a three times weekly schedule for 4 out of every 6 weeks. This schedule was based on the observation that prolonged administration of NMF was associated with the most efficacious antitumor activity in preclinical studies. Phase II trials that employed a starting dose of 800 mg/m2, determined in a previous phase I trial, were suspended because of frequent and severe toxicities. In the current study, a symptom complex characterized by nausea, vomiting, and malaise was the dose-limiting toxicity of oral NMF administered on this schedule. Other toxicities included hepatic enzyme elevations, mild myelosuppression, and worsening of preexistent toxic peripheral neuropathies. Of interest, three patients who were asymptomatic prior to treatment, rapidly developed symptoms of increased intracranial pressure after starting NMF; and, computerized tomographic brain scans revealed metastatic tumors with significant peritumoral edema. NMF was well tolerated at 600 mg/m2, however, an abrupt increase in toxicity resulted when the dose was increased to 700 mg/m2. Although NMF peak plasma concentrations (Cmax) and areas under the plasma disappearance curves (AUC) differed between the 600 and 700 mg/m2 dose levels, these differences were not striking, and similar NMF plasma concentrations and exposures were well tolerated during intravenous trials. Based on this study, the recommended phase II dose for oral NMF administered three times weekly for 4 of 6 weeks was 600 mg/m2. Cmaxs and AUCs at this dose were significantly lower than those that were demonstrated to induce cytotoxicity, and differentiating, chemosensitizing, and radiosensitizing effects in preclinical studies suggesting that further clinical evaluations of NMF may not be warranted.
Similar content being viewed by others
References
Clarke DA, Philips FS, Sternberg SS, Barclay RK, Stock CC: Effects of n-methylformamide and related compounds in mouse sarcoma 180. Proc Soc Exp Biol Med 84:203–207, 1983
Gescher A, Gibson NW, Hickman JA, Langdon SP, Ross D, Atassi G: N-methylformamide: antitumor activity and metabolism in mice. Br J Cancer 45:843–849, 1982
Furst A, Cutting WC, Gross H: Retardation of growth of Erlich ascites tumor by formamides and related compounds. Cancer Res 15:294–299, 1955
National Cancer Institute: N-methylformamide (NMF NSC 3051). Clinical Brochure. Division of Cancer Treatment, National Cancer Institute, Bethesda, Maryland
Langdon SP, Hickman JA, Gescher A, Stevens FG, Chubb D, Vickers LM: N-methylformamide (NSC 3051): a potential candidate for combination chemotherapy. Eur J Cancer Clin Oncol 21:745–752, 1985
Spremulli EN, Dexter DL: Polar solvents; a novel class of antineoplastic agents: J Clin Oncol 2:227–241, 1984
Tanaka M, Levy J, Terada M, Breslow R, Rifkind R, Marks P: Induction of erythroid differentiation in murine virus infected erythroleukemia by highly polar compounds. Proc Natl Acad Sci USA 72:1003–1006, 1975
Collins SJ, Ruscetti FW, Gallagher RE, Gallo RC: Terminal differentiation of human promyelocytic leukemia cells by dimethyl sulfoxide and other polar planar compounds. Proc Natl Acad Sci 75:2458–2462, 1978
Dexter DL, Barbosa JA, Calabresi P: N,N-Dimethylforma-mide-induced alteration of cell culture characteristics and loss of tumorgenicity in cultured human colon carcinoma cell lines. Cancer Res 39:1020–1025, 1979
Hager JC, Gold DV, Barbosa JA, Fligiel Z, Miller F, Dexter D: N,N-Dimethylformamide-induced modulation of organ- and tumor-associated markers in cultured human colon carcinoma cells. J Natl Cancer Inst 64:439–446, 1980
Dexter DL, Spermulli EN, Savarese TM: Effects of N-methylformamide (N-MF) on murine and human cancer cells. Clin Res 30:532A, 1982
Arundel C, Bock S, Brock WA, Tofilon PJ: Radiosensitization of primary human tumor cell cultures by N-methylformamide. Int J Radiat Oncol Biol Phys 13:753–757, 1987
Iwakawa M, Milas L, Hunter N, Tofilon PJ: Modification of tumor and normal tissue radioresponse in mice by N-methylformamide. Int J Radiat Oncol Biol Phys 13:55–60, 1987
Glicksman AS, Lee ES, Leite D, Leith JT: Production of increased cytotoxicity in human colon tumor cells after x-irradiation or drug treatment (cis-platinum, bleomycin, 5-fluorouracil) by pre-exposure to the differentiating agent N-methylformamide (NMF). (Abstr) Proc Amer Soc Clin Oncol 5:45, 1986
Tofilon PJ, Vines CM, Milas L: N-methylformamidemediated enhancement of in vitro tumor cell chemosensitivity. Cancer Chemother Pharmacol 17:269–273, 1986
Dexter DL, DeFusco DJ, McCarthy K, Calabresi P: Polar solvents increase the sensitivity of cultured human colon cancer cells to cis-platinum and mitomycin-C. (Abstr) Proc Am Assoc Can Res 24:267, 1983
Harpur ES, Langdon SP, Fathalla SA, Ishmael J: The antitumor effect and toxicity of cis-platinum and N-methylformamide in combination. Cancer Chemother Pharmacol 16:139–147, 1986
Myers WPL, Karnofsky DA, Burchenal JH: The hepatotoxic action of N-methylformamide in man. Cancer 9:949–954, 1956
Spremulli EN, Dexter DL, Cummings FJ, Wieman M, Salvatore J, Smith D, Matook G, Crabtree GW, Griffiths W, Calabresi P: Phase I clinical and pharmacological studies of monomethylformamide (N-MF). (Abstr) Proc Amer Soc Clin Oncol 2:24, 1983
Ettinger DS, Orr DW, Rice AP, Donehower RC: Phase I study of N-methylformamide in patients with advanced cancer. Cancer Treat Rep 69:489–493, 1985
MeVie JG, ten Bokkel Huinink WW, Simonetti G, Dubbelman R: Phase I trial of N-methylformamide. Cancer Treat Rep 68:607–610, 1984
O'Dwyer PJ, Donehower M, Sigman LM, Fortner CL, Aisner J, Van Echo DA: Phase I trial of N-methylformamide (NFM, NSC 3051). J Clin Oncol 3:853–857, 1985
Murphy SB, Mirro Jr J, Pui CH, Pratt CB: Phase I trial of N-methylformamide in pediatric patients with refractory leukemias. Cancer Treat Rep 71:1299–1300, 1987
Sterberg CN, Yagoda A, Scher HI, Hollander P: Phase II trial of N-methylformamide for advanced renal cell carcinoma. Cancer Treat Rep 70:681–682, 1986
Planting AST, Klign JGM, Verweij J, Stoter G: Phase II study on oral N-methylformamide in metastatic colorectal cancer. Cancer Treat Rep 71:1293–1294, 1987
Tchekmedyian NS, Kaplan RS, Eisenberger M, Abrams J, Van Echo D: Phase II study of N-methylformamide in patients with advanced colorectal cancer. Cancer Treat Rep 71:541–542, 1987
Ettinger DS, Finkelstein DM, Donehower RC, Chang AYC, Green M, Blum R, Hahn RG, Ruckdeschel JC. Phase II study of N-methylformamide in the treatment of non-small cell lung cancer (EST 3583): an eastern cooperative group study. Med Ped Onc 17:197–201, 1989
Vogel WC, Forastiere AA, Natale RB, Takasu;gi BJ, Schnur G: Phase II trial of N-methylformamide in advanced head and neck cancer. Invest New Drugs 5:203–206, 1987
Brindley C, Gescher A, Harpur ES, Ross D, Slack JA, Threadgill MD, Whitby H: Studies of the pharmacology of N-methylformamide in mice. Cancer Treat Rep 66:1957–1965
McVie JG, ten Bokkel Huinink WW, Newlands E, Simonetti G, Slack J: Phase I studies and clinical pharmacology of N-methylformamide (NSC 3051, NMF). (Abstr) Proc Amer Soc Clin Oncol 2:34, 1983
Wiemann MC, Cummings FJ, Posner MR, Weens JH, Crabtree P, Birmingham BK, Moore A, Calabresi P: Phase I clinical and pharmacological trial of oral N-methylformamide (NMF). (Abstr) Proc Amer Soc Clin Oncol 4:38, 1985
Eisenhauer EA, Weinerman BH, Kerr I, Quirt I: Toxicity of oral N-methylformamide in three phase II trials: a report from the National Cancer Institute of Canada Clinical Trials Group. Cancer Treat Rep 70:881–883, 1986
Rowinsky EK, Noe DA, Orr DW, Grochow LB, Ettinger DS, Donehower RC: Clinical pharmacology of oral and intravenous n-methylformamide: a pharmacologic basis for lack of clinical antineoplastic activity. J Natl Cancer Inst 80:671–678, 1988
Oken, Creech R, Tormey D: Toxicity and response criteria of the eastern cooperative oncology group. Am J Clin Oncol 5:649–655, 1982
Sternberg CN, Yagoda A: N-methylformamide-induced hypophosphatemia. Cancer Treat Rep 69:343–344, 1985
Weissman DE, Grossman SA: A model for quantitation of peritumoral brain edema. J Neurosci Methods 23:207–210, 1988
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Rowinsky, E.K., Grochow, L.B., Hantel, A. et al. Assessment of N-methylformamide (NMF) administered orally on a three times weekly schedule: a phase I study. Invest New Drugs 7, 317–325 (1989). https://doi.org/10.1007/BF00173761
Issue Date:
DOI: https://doi.org/10.1007/BF00173761